Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660568 | 0.92 | OPRM1 (0.34) | CCR1DRD2OPRM1ADRA2AADRA2B | |
| SCHEMBL653882 | 0.88 | CCR1 (0.35) | CCR1DRD2OPRM1OPRL1 | |
| SCHEMBL655810 | 0.88 | DRD2 (0.34) | CCR1DRD2OPRM1SLC6A4HRH1 | |
| SCHEMBL654374 | 0.88 | CCR1 (0.35) | CCR1DRD2 | |
| SCHEMBL652741 | 0.87 | CCR1 (0.39) | CCR1DRD2OPRM1OPRL1 | |
| SCHEMBL655073 | 0.87 | CCR1 (0.37) | CCR1DRD2OPRM1ADRA2AADRA2B | |
| SCHEMBL653230 | 0.86 | CCR1 (0.36) | CCR1DRD2OPRM1SLC6A4HRH1 | |
| SCHEMBL652813 | 0.86 | ALDH1A1 (0.38) | CCR1DRD2ADRA1A | |
| SCHEMBL653796 | 0.85 | CCR1 (0.35) | CCR1DRD2ADRA1A | |
| SCHEMBL658012 | 0.85 | CCR1 (0.34) | CCR1DRD2OPRM1ADRA1AOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937060-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2015-01-20 | — | — | US | claimed |
| US-20110152284-A1 | Sigma ligands for neuronal regeneration and functional recovery | WIELOCH TADEUSZ | 2011-06-23 | — | — | US | claimed |
| US-20090012081-A1 | Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2009-01-08 | — | — | US | claimed |
| US-20060241168-A1 | Antidepressant | OHKAWA SHIGENORI | 2006-10-26 | — | — | US | claimed |
| US-7008950-B1 | Benzofurans as suppressors of neurodegeneration | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-07 | — | — | US | claimed |
| US-20050171135-A1 | 1'-[4-[1-(4-fluorophenyl)-1H-indole-3-Y1]-spiro[isobenzofuran-1(3H), 4'-piperidine]hydrohalogenides | H. LUNDBECK A/S (DK) | 2005-08-04 | — | — | US | claimed |
| US-6448247-B1 | TACHYKININ RECEPTOR ANTAGONIST; ESPECIALLY TO THE RECEPTORS FOR SUBSTANCE P (WHICH RECEPTORS ARE GENERALLY REFERRED TO AS ?NEUROKININ 1 RECEPTORS?) | SANKYO COMPANY, LIMITED (JP) | 2002-09-10 | — | — | US | claimed |
| US-6436938-B1 | ADMINISTERING A SIGMA RECEPTOR LIGAND IN COMBINATION WITH AN ANTIDEPRESSANT AGENT; ESPECIALLY FOR REFRACTORY DEPRESSION | PFIZER INC. | 2002-08-20 | — | — | US | claimed |
| US-20020099045-A1 | Combination treatment for depression | PFIZER PRODUCTS INC. | 2002-07-25 | — | — | US | claimed |
| EP-1224930-A1 | Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression | Pfizer Products Inc. (US) | 2002-07-24 | — | — | EP | claimed |
| US-20020004601-A1 | Spiro[cyclopent[b]indole-piperidines] | HOECHST MARION ROUSSEL, INC. | 2002-01-10 | — | — | US | claimed |
| EP-0892802-A1 | SPIRO(CYCLOPENT(B)INDOLE-PIPERIDINES) AND N-PHENYL-HYDRAZON INTERMEDIATES FOR THEIR PREPARATION, BOTH BEING ACETYLCHOLINESTERASE AND MAO INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1999-01-27 | — | — | EP | claimed |
| CN-1175256-A | tetracyclic spiro compounds, process for their preparation and their use as 5HT1D receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 1998-03-04 | — | — | CN | claimed |
| WO-1997037992-A2 | SPIRO[CYCLOPENT[B]INDOLE-PIPERIDINES] AND N-PHENYL-HYDRAZON INTERMEDIATES FOR THEIR PREPARATION, BOTH BEING ACETYLCHOLINESTERASE AND MAO INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1997-10-16 | — | — | WO | claimed |
| CN-1157286-A | N,N-dimethyl-1-t-butoxycarbonyl-4-phenylpiperidine-4-carboxamide | SANKYO CO (JP) | 1997-08-20 | — | — | CN | claimed |
| WO-2024140679-A1 | SPIROCYCLIC HPK1 ANTAGONISTS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-07-04 | — | — | WO | disclosed |
| EP-4288436-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | HUTCHMED Limited (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-4552881-A | CARDIOVASCULAR DISORDERS | MERCK & CO., INC. (US) | 1985-11-12 | — | — | US | disclosed |
| EP-0104632-A2 | 1'-(3-(1,2-Benzisoxazol-3-yl)propyl)spiro-(benzofuran-2-(3H),3' or 4'-piperidine or 3'-pyrrolidines), a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1984-04-04 | — | — | EP | disclosed |
| EP-0104632-A2 | 1'-(3-(1,2-Benzisoxazol-3-yl)propyl)spiro-(benzofuran-2-(3H),3' or 4'-piperidine or 3'-pyrrolidines), a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152284-A1 | Sigma ligands for neuronal regeneration and functional recovery | SIGMAR1, TMEM97, LPAR6 | CCR1 899/4885DRD2 729/4885OPRM1 38/4885 |
| US-20060241168-A1 | Antidepressant | AKT1S1, AKT1, AKT2 | CCR1 3034/4885DRD2 224/4885OPRM1 146/4885 |
| US-20090012081-A1 | Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells | NES, MKI67, CCNO | CCR1 807/4885DRD2 2003/4885OPRM1 1201/4885 |
| US-20020099045-A1 | Combination treatment for depression | HTR5A, HTR1A, OPRL1 | CCR1 1684/4885DRD2 151/4885OPRM1 22/4885 |
| US-20050171135-A1 | 1'-[4-[1-(4-fluorophenyl)-1H-indole-3-Y1]-spiro[isobenzofuran-1(3H), 4'-piperidine]hydrohalogenides | TPH1, HTR1D, TPH2 | CCR1 3291/4885DRD2 50/4885OPRM1 257/4885 |
| US-20020004601-A1 | Spiro[cyclopent[b]indole-piperidines] | CAMK2B, GRIN2B, HTR2B | CCR1 1603/4885DRD2 32/4885OPRM1 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.